Ultragenyx Pharmaceutical Inc. (RARE) announced after the bell Tuesday that its Phase 3 study of aceneuramic acid extended release in patients with GNE Myopathy failed to meet its primary endpoint of demonstrating a statistically significant difference in the upper extremity muscle strength composite score compared to placebo.
from RTT - Before the Bell http://ift.tt/2viUEEk
via IFTTT
No comments:
Post a Comment